<DOC>
	<DOCNO>NCT01401036</DOCNO>
	<brief_summary>Drug-eluting stent reduce rate restenosis reintervention , compare uncoated stent . Data limit regard safety efficacy Nobori ( Biolimus A9 Eluting Stent ) primary percutaneous coronary intervention ( PCI ) acute myocardial infarction ( AMI ) . Accordingly , investigator compare outcomes primary PCI AMI patient receive Nobori versus uncoated stent .</brief_summary>
	<brief_title>Nobori And Uncoated Stent In Coronary Attack</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>age 20 year old chest pain last 20 min symptom begin within 12 hour characterization electrocardiogram show STsegment elevation new appearance leave bundle branch block increase cardiac enzymes 5fold normal laboratory value infarctrelated vessel anatomically suitable percutaneous revascularization patient give sign , inform consent previous stent implantation within 30 day allergy following : aspirin , heparin , clopidogrel , biolimus A9 derivative , stainless steel 316L , PLA ( PolyLactic Acid ) Polymer derivative , contrast medium elective surgery schedule within 6 month renal insufficiency creatinine level 2.5 mg/dL patient associate bleed and/or clot disorder , refuse blood transfusion history massive gastrointestinal urinary tract bleed within 6 month patient currently enrol clinical trial pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>acute myocardial infarction</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>thrombosis</keyword>
</DOC>